Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04790175
Other study ID # 156-101-00348
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 29, 2021
Est. completion date January 2030

Study information

Verified date November 2023
Source Otsuka Pharmaceutical Co., Ltd.
Contact Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
Phone +81-6-6943-7722
Email komaniwa.satoshi@otsuka.jp
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date January 2030
Est. primary completion date August 2028
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Subjects with a definite diagnosis of SIADH in reference to "Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2018" Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tolvaptan (SAMSCA)
The usual adult dose of SAMSCA is 7.5 mg of tolvaptan once daily administered orally, increased stepwise to 60 mg daily until a desirable level of serum sodium concentration is achieved.

Locations

Country Name City State
Japan Pharmacovigilance Department Osaka

Sponsors (1)

Lead Sponsor Collaborator
Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Information (Adverse Event) Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (ICH-E2A Guideline).
An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product (Samsca), whether or not it is considered causally related to the Medicinal Product.
90 days from the initiation of tolvaptan treatment
Primary Safety Information (Special Situations) Situations related to the use of an Otsuka product which may or may not be associated with an adverse event:
Maternal (pregnancy and breastfeeding) or paternal (via semen) exposure;
Exposure during breastfeeding;
Overdose/Incorrect dosage, misuse, abuse (e.g. patient sharing products);
Medication errors (e.g. patient took wrong dose);
Lack of therapeutic efficacy (e.g. the product doesn't work);
Occupational exposure (e.g.: nurse administering the product is exposed);
Cases of suspected transmission of infectious agents;
Use of suspected or confirmed falsified product(s) or quality defect of the product(s);
Withdrawal reactions;
Accidental exposure (e.g.: child takes parent's product);
Drug-drug/drug-food interactions;
Unintentional use of product in a non-approved population (e.g.: pediatric or geriatric population);
Disease progression/exacerbation of existing disease
90 days from the initiation of tolvaptan treatment
Primary Safety Information (Number of off-Label Use) Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in non-authorized population categories not indicated in the label. 90 days from the initiation of tolvaptan treatment
Primary Safety Information (Serious Adverse Event) Any adverse drug experience/event occurring at any dose which
results in death
is life-threatening
requires inpatient hospitalization or prolonged of existing hospitalization
results in persistent or significant disability or incapacity
is a congenital anomaly/birth defect
is medically significant.
90 days from the initiation of tolvaptan treatment
Primary Safety Information (Non-serious Adverse Events) All Adverse Events that do not meet the definition of a serious Adverse Event are considered non-serious Adverse Events. 90 days from the initiation of tolvaptan treatment